Cantillon Capital Management LLC Purchases 413,256 Shares of IQVIA Holdings Inc. $IQV

Cantillon Capital Management LLC grew its position in IQVIA Holdings Inc. (NYSE:IQV) by 27.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,926,934 shares of the medical research company’s stock after acquiring an additional 413,256 shares during the quarter. IQVIA comprises about 2.0% of Cantillon Capital Management LLC’s portfolio, making the stock its 25th largest position. Cantillon Capital Management LLC owned 1.13% of IQVIA worth $366,002,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in IQV. Alliancebernstein L.P. lifted its stake in IQVIA by 0.6% in the second quarter. Alliancebernstein L.P. now owns 3,555,929 shares of the medical research company’s stock worth $560,379,000 after purchasing an additional 19,573 shares during the last quarter. Artisan Partners Limited Partnership bought a new stake in shares of IQVIA during the 2nd quarter worth approximately $515,772,000. JPMorgan Chase & Co. boosted its holdings in IQVIA by 22.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock valued at $492,659,000 after acquiring an additional 581,157 shares during the period. Nordea Investment Management AB grew its position in IQVIA by 12.3% in the 3rd quarter. Nordea Investment Management AB now owns 2,314,219 shares of the medical research company’s stock valued at $421,257,000 after acquiring an additional 253,759 shares during the last quarter. Finally, Lazard Asset Management LLC increased its stake in IQVIA by 6.1% in the second quarter. Lazard Asset Management LLC now owns 1,866,537 shares of the medical research company’s stock worth $294,145,000 after purchasing an additional 107,500 shares during the period. 89.62% of the stock is currently owned by institutional investors.

IQVIA Trading Down 0.9%

IQVIA stock opened at $239.15 on Friday. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04. The stock has a market cap of $40.73 billion, a PE ratio of 32.81, a price-to-earnings-growth ratio of 2.46 and a beta of 1.36. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. The stock has a 50-day moving average of $228.82 and a two-hundred day moving average of $205.11.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.98 by $0.02. The firm had revenue of $4.10 billion for the quarter, compared to the consensus estimate of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Barclays set a $230.00 price target on shares of IQVIA in a report on Monday, December 15th. Citigroup upped their target price on shares of IQVIA from $200.00 to $230.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 29th. Wall Street Zen downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday, January 17th. Hsbc Global Res raised IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 9th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $251.06.

Insider Activity at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the sale, the insider directly owned 27,108 shares of the company’s stock, valued at $5,955,627.60. The trade was a 12.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.60% of the company’s stock.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.